Across all 3 studies, Bacopa showed beneficial effects on improved attention span, with statistically significant findings in each case. The predominant effect size was small, with one systematic review reporting moderate effects. Effects were typically observed at 60 days based on limited duration data, and one RCT used a dose of 160 mg/day in a clinical population with mild cognitive impairment.
Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Most studies did not report form or dose, and the highest-quality study (systematic review) did not dose or duration details, limiting practical application.
Bacopa monnieri consistently improved inattention, hyperactivity, and memory
While in the field of attention at the end of the first month (P = 0.033) and the end of the second month (P = 0.004), it was significant difference between the study groups.
BM can reduce Nuclear Factor-κB phosphorylation, improve emotional function, cognitive functions, anhedonia, hyperactivity, sleep routine, depression, attention deficit, learning problems, memory retention, impulsivity, and psychiatric problems.